[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 24 of about 24
1. Pagliaro LC, Williams DL, Daliani D, Williams MB, Osai W, Kincaid M, Wen S, Thall PF, Pettaway CA: Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study. J Clin Oncol; 2010 Aug 20;28(24):3851-7
Hazardous Substances Data Bank. IFOSFAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant paclitaxel, ifosfamide, and cisplatin chemotherapy for metastatic penile cancer: a phase II study.
  • PURPOSE: Men with penile squamous cell carcinoma and regional lymph node involvement have a low probability of survival with lymphadenectomy alone.
  • A multimodal approach to treatment is desirable for such patients.
  • We performed a phase II study of neoadjuvant chemotherapy with the objective of determining the response rate, time to progression (TTP), and overall survival (OS) among patients with bulky adenopathy.
  • PATIENTS AND METHODS: Eligible patients had stage N2 or N3 (stage III or stage IV) penile cancer without distant metastases.
  • Neoadjuvant treatment (four courses every 3-4 weeks) consisted of paclitaxel 175 mg/m(2) administered over 3 hours on day 1; ifosfamide 1,200 mg/m(2) on days 1 to 3; and cisplatin 25 mg/m(2) on days 1 to 3.
  • RESULTS: Thirty men received chemotherapy of whom 15 (50.0%) had an objective response and 22 (73.3%) subsequently underwent surgery.
  • Improved TTP and OS were significantly associated with a response to chemotherapy (P < .001 and P = .001, respectively), absence of bilateral residual tumor (P = .002 and P = .017, respectively), and absence of extranodal extension (P = .001 and P = .004, respectively) or skin involvement (P = .009 and P = .012, respectively).
  • CONCLUSION: The neoadjuvant regimen of paclitaxel, ifosfamide, and cisplatin induced clinically meaningful responses in patients with bulky regional lymph node metastases from penile cancer.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / secondary. Lymph Node Excision. Neoadjuvant Therapy / methods. Penile Neoplasms / drug therapy. Penile Neoplasms / pathology
  • [MeSH-minor] Adult. Aged. Chemotherapy, Adjuvant. Cisplatin / administration & dosage. Disease-Free Survival. Drug Administration Schedule. Humans. Ifosfamide / administration & dosage. Kaplan-Meier Estimate. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Paclitaxel / administration & dosage. Predictive Value of Tests. Prospective Studies. Radiotherapy, Adjuvant. Risk Factors. Treatment Outcome

  • Genetic Alliance. consumer health - Metastatic cancer.
  • COS Scholar Universe. author profiles.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Head Neck. 2007 Jan;29(1):38-46 [17103410.001]
  • [Cites] J Surg Oncol. 2006 Feb 1;93(2):133-8 [16425300.001]
  • [Cites] Nat Clin Pract Urol. 2007 Mar;4(3):140-6 [17347658.001]
  • [Cites] J Urol. 2007 Apr;177(4):1335-8 [17382727.001]
  • [Cites] Eur Urol. 2007 Aug;52(2):488-94 [17316964.001]
  • [Cites] Ann Oncol. 2008 Jul;19(7):1304-7 [18417462.001]
  • [Cites] World J Urol. 2009 Apr;27(2):141-50 [18607597.001]
  • [Cites] World J Urol. 2009 Apr;27(2):189-96 [18636264.001]
  • [Cites] CA Cancer J Clin. 2009 Jul-Aug;59(4):225-49 [19474385.001]
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Nov 1;48(4):1007-13 [11072157.001]
  • [Cites] J Urol. 2002 Apr;167(4):1638-42 [11912379.001]
  • [Cites] Lancet Oncol. 2004 Apr;5(4):240-7 [15050955.001]
  • [Cites] Cancer Chemother Rep. 1966 Mar;50(3):163-70 [5910392.001]
  • [Cites] Cancer. 1973 Nov;32(5):1256-62 [4757915.001]
  • [Cites] J Urol. 1987 May;137(5):880-2 [3573181.001]
  • [Cites] Acta Oncol. 1988;27(6b):823-4 [2466471.001]
  • [Cites] J Urol. 1993 Mar;149(3):492-7 [8437253.001]
  • [Cites] Br J Urol. 1993 Nov;72(5 Pt 2):817-9 [8281416.001]
  • [Cites] J Urol. 1996 Nov;156(5):1637-42 [8863559.001]
  • [Cites] Lancet. 1996 Oct 19;348(9034):1049-54 [8874455.001]
  • [Cites] J Clin Oncol. 1998 Apr;16(4):1325-30 [9552033.001]
  • [Cites] Stat Med. 1998 Jul 30;17(14):1563-80 [9699230.001]
  • [Cites] J Urol. 1999 Jun;161(6):1823-5 [10332445.001]
  • [Cites] J Urol. 2007 Mar;177(3):947-52; discussion 952 [17296384.001]
  • (PMID = 20625118.001).
  • [ISSN] 1527-7755
  • [Journal-full-title] Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • [ISO-abbreviation] J. Clin. Oncol.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA140388; United States / NCI NIH HHS / CA / CA016672
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin; UM20QQM95Y / Ifosfamide
  • [Other-IDs] NLM/ PMC2940402
  •  go-up   go-down


2. Berney DM, Stankiewicz E, Adlan AM, Kudahetti S, Biedrzycki OJ, Hadway P, Watkin N, Corbishley C: DNA topoisomerase I and IIalpha expression in penile carcinomas: assessing potential tumour chemosensitivity. BJU Int; 2008 Sep;102(8):1040-4
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] DNA topoisomerase I and IIalpha expression in penile carcinomas: assessing potential tumour chemosensitivity.
  • OBJECTIVE: To examine the tissue expression of DNA topoisomerase I (Topo I) and IIalpha (Topo II), to pursue the possibility of future chemotherapy regimens for squamous cell carcinoma of the penis (SCCP), as high expression of Topo I might indicate sensitivity to the camptothecins, whereas high Topo II might indicate sensitivity to etoposide.
  • PATIENTS AND METHODS: In all, 73 patients with SCCP were reviewed and then tissue samples microarrayed.
  • Tumour stage, grade and type were available.
  • Tumour type was also strongly correlated with Topo II and Ki-67 expression, with the highest expression in basaloid carcinomas and the lowest in verrucous carcinomas.
  • CONCLUSION: The expression of Topo I is grade- and type-independent, and chemotherapy using the camptothecins is unlikely to be effective.
  • The strong positivity of Topo II in high-grade and basaloid SCCPs suggests that treatment with etoposide or other Topo II 'poisons' might be a better target for future clinical trials.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / metabolism. Carcinoma, Squamous Cell / enzymology. DNA Topoisomerases, Type I / metabolism. DNA Topoisomerases, Type II / metabolism. DNA-Binding Proteins / metabolism. Penile Neoplasms / enzymology
  • [MeSH-minor] Drug Resistance, Neoplasm. Humans. Immunohistochemistry. Ki-67 Antigen / metabolism. Male

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18489530.001).
  • [ISSN] 1464-410X
  • [Journal-full-title] BJU international
  • [ISO-abbreviation] BJU Int.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 0 / Ki-67 Antigen; EC 5.99.1.2 / DNA Topoisomerases, Type I; EC 5.99.1.3 / DNA Topoisomerases, Type II; EC 5.99.1.3 / DNA topoisomerase II alpha
  •  go-up   go-down


3. García Rodríguez J, Fernández Gómez JM, Rodríguez Martínez JJ, Rodríguez Faba O, Jalón Monzón A, San Martín Blanco A, Martínez Gómez FJ, Sánchez Trilla A, Martín Benito JL, Escaf Barmadah S, Regadera Sejas J: [Clinical course of epidermoid carcinoma of the penis in our series]. Arch Esp Urol; 2003 Jan-Feb;56(1):30-6
Genetic Alliance. consumer health - Epidermoid Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical course of epidermoid carcinoma of the penis in our series].
  • [Transliterated title] Análisis de la evolución del carcinoma epidermoide de pene en nuestra serie.
  • OBJECTIVES: To study the evolution of 49 patients with squamous cell carcinoma of the penis.
  • METHODS: 49 patients who underwent surgery for squamous cell carcinoma of the penis (30 partial penile amputations, 11 total amputations and 7 circumcisions).
  • 27 inguinal lymphadenectomies, superficial, profound and ilio-obturator (2 cases), were performed due to persistent lymph nodes after penile amputation despite of antibiotic treatment for 4 weeks, or to high grade primary tumour.
  • 13 patients were found to have lymph node metastases after treatment, receiving posterior adjuvant treatment with radiotherapy, chemotherapy or a combination of them.
  • Patients were followed in relation to stage, cell differentiation degree, and presence or absence of positive lymph nodes and distant metastases.
  • 6 patients died from tumour dissemination, 2 of them were T2G2, one T2G1, and three T1G2; two additional patients died from causes different from the tumour, all of them being N+ at the time of diagnosis.
  • CONCLUSIONS: Penile squamous cell carcinoma is an aggressive tumour the evolution of which mainly depends on the local-regional stage at the time of diagnosis and cell differentiation; these factors will condition lymphadenectomy versus observation.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Carcinoma, Squamous Cell / surgery. Penile Neoplasms / pathology. Penile Neoplasms / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12701478.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


Advertisement
4. Skripuletz T, Pul R, Herrmann J, Bueltmann E, Wurster U, Stangel M, Trebst C: Meningeal carcinomatosis from penile squamous cell carcinoma. J Neurooncol; 2010 Jul;98(3):417-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Meningeal carcinomatosis from penile squamous cell carcinoma.
  • We report herein a clinical case of a patient with meningeal carcinomatosis from penile squamous cell carcinoma.
  • Examinations revealed brain metastases and infiltration of the leptomeninges and subarachnoid space by carcinoma cells.
  • Only 11 months earlier the patient had been diagnosed with penile squamous cell carcinoma of poor differentiation and had underwent subtotal penectomy and adjuvant chemotherapy and radiation.
  • Infiltration of the central nervous system with penile cancer is extremely rare, and only five cases with brain metastases have been described to date.
  • This is the first report of a patient with penile cancer spread to the leptomeninges.
  • [MeSH-major] Carcinoma / secondary. Carcinoma, Squamous Cell / pathology. Meningeal Carcinomatosis / secondary. Penile Neoplasms / pathology
  • [MeSH-minor] Aged. Humans. Male. Tomography Scanners, X-Ray Computed

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 2004 Sep 15;101(6):1357-63 [15316902.001]
  • [Cites] J Neurooncol. 1998 Jun-Jul;38(2-3):121-5 [9696361.001]
  • [Cites] J Neurooncol. 2009 Sep;94(2):229-34 [19267183.001]
  • [Cites] J Urol. 2003 Aug;170(2 Pt 1):359-65 [12853775.001]
  • [Cites] Wiad Lek. 1992 Apr;45(7-8):314-6 [1462597.001]
  • [Cites] J Am Osteopath Assoc. 2008 Jun;108(6):310-2 [18587080.001]
  • [Cites] J Neurooncol. 2003 May;63(1):63-7 [12814256.001]
  • [Cites] J Neurooncol. 1992 May;13(1):81-9 [1613540.001]
  • [Cites] Urology. 2005 Aug;66(2):432 [16098372.001]
  • [Cites] Int J Surg Pathol. 2011 Apr;19(2):164-9 [19411278.001]
  • [Cites] Oncologist. 2008 Sep;13(9):967-77 [18776058.001]
  • (PMID = 20013145.001).
  • [ISSN] 1573-7373
  • [Journal-full-title] Journal of neuro-oncology
  • [ISO-abbreviation] J. Neurooncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


5. Marconnet L, Bouchot O, Culine S, Avances C, Rigaud J, membres du CCAFU-OGE: [Treatment of lymph nodes in epidermoid carcinoma of the penis: review of literature by the Committee of Cancerology of the French Association of Urology-External Genital Organs Group (CCAFU-OGE)]. Prog Urol; 2010 May;20(5):332-42
Genetic Alliance. consumer health - Epidermoid Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of lymph nodes in epidermoid carcinoma of the penis: review of literature by the Committee of Cancerology of the French Association of Urology-External Genital Organs Group (CCAFU-OGE)].
  • [Transliterated title] Prise en charge ganglionnaire dans le carcinome épidermoïde du pénis: revue de la littérature par le comité de cancérologie de l'Association française d'urologie-groupe organes génitaux externes (CCAFU-OGE).
  • INTRODUCTION: Invasive lymph nodes are an independent factor of prognosis and essential for the survival of patients with cancer of the penis.
  • The aim of this article is to analyse published research results on the diagnosis and treatment of lymph nodes in cancer of the penis.
  • MATERIAL AND METHOD: Bibliographic research on Medline was carried out using the terms penile carcinoma, lymph node dissection, lymphadenectomy, survival, chemotherapy and radiotherapy.
  • A diagnosis of suspected adenopathy based on clinical examination associated with FNA biopsy is essential.
  • Not only is surgery on inguinal lymph nodes the only reliable way of confirming an invasive metastatic lymph node, it also plays a therapeutic and prognostic role for patients who have a tumour of the penis which risks spreading to lymph nodes (intermediate or high risk according to EAU).
  • The type of dissection is in function with the clinical examination: a radical inguinal dissection is recommended in the case of palpated adenopathy and a modified inguinal dissection is recommended if there is no palpated adenopathy, this should be radicalised in the case of metastatic adenopathy on histological examination.
  • Neo-adjuvant or adjuvant chemotherapy would appear to play a interesting role when combined with surgery for certain patients without there being currently being precise consensus because of the lack of documented cases.
  • CONCLUSION: Lymph node dissection alone has a therapeutic role in patients who have reached metastasis of lymph nodes (stage pN1).
  • Consequently, it would seem important to develop multimodal approaches in the treatment of these patients in order to increase the rate of response to treatment.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Lymph Node Excision. Penile Neoplasms / surgery
  • [MeSH-minor] Chemotherapy, Adjuvant. France. Humans. Lymphatic Metastasis. Male. Neoplasm Invasiveness. Societies, Medical. Urology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.
  • (PMID = 20471577.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 65
  •  go-up   go-down


6. Tan JM, Jin XL, Gao Y, Xu DF, Zhou WM, Zhang TL, Xu JJ, Fu XH: [Treatment of 58 cases of penile squamous cell carcinoma]. Zhonghua Nan Ke Xue; 2010 Sep;16(9):822-5
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment of 58 cases of penile squamous cell carcinoma].
  • OBJECTIVE: To search for rational and effective treatments for penile squamous cell carcinoma (PSCC).
  • METHODS: We retrospectively analyzed the clinical data of 58 cases of pathologically confirmed PSCC, focusing on the treatment methods.
  • Fifty-three of the patients were treated by surgery, of whom 43 underwent limited resection of the tumor or partial amputation of the penis, and the other 10 received total penis amputation plus perineal urethrostomy and clearance of lymphoglandulae iliacae and inguinal lymph nodes, with the lymphoglandulae iliacae positive in 1 case and the inguinal lymph nodes positive in all.
  • Thirty-seven cases received neoadjuvant hormonal therapy (thermotherapy plus chemotherapy) and combined postoperative chemotherapy, 12 postoperative chemotherapy only, and 4 merely surgery.
  • Five of the total number underwent chemotherapy and/or radiotherapy without surgery.
  • The 2-5 years follow-up of 48 patients found recurrence in 4 cases of partial penis amputation within 2 years, 4 deaths within 2 years, 7 deaths from 2 to 5 years.
  • CONCLUSION: Surgery + neoadjuvant hormonal therapy + postoperative chemotherapy and/or radiotherapy is an effective method for PSCC, but whether it can reduce the recurrence of PSCC and improve the survival of the patients remains to be further studied.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Penile Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Humans. Male. Middle Aged. Neoplasm Staging. Retrospective Studies. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21171268.001).
  • [ISSN] 1009-3591
  • [Journal-full-title] Zhonghua nan ke xue = National journal of andrology
  • [ISO-abbreviation] Zhonghua Nan Ke Xue
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


7. Bermejo C, Busby JE, Spiess PE, Heller L, Pagliaro LC, Pettaway CA: Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma. J Urol; 2007 Apr;177(4):1335-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neoadjuvant chemotherapy followed by aggressive surgical consolidation for metastatic penile squamous cell carcinoma.
  • PURPOSE: Combination chemotherapy for advanced penile cancer can produce partial response rates of up to 64%.
  • Complete responses are rare, suggesting a need for adjunct therapies to facilitate cure.
  • We evaluated patients with metastases who underwent surgical consolidation after responding to chemotherapy.
  • MATERIALS AND METHODS: We reviewed the records of 59 patients with advanced penile carcinoma treated from 1985 to 2000 and identified 10 treated with surgical consolidation after demonstrating a stable, partial or complete response to chemotherapy.
  • RESULTS: After chemotherapy 4 patients had a complete response, 1 had a partial response and 5 had stable disease.
  • All 3 patients received ifosfamide, paclitaxel and cisplatin chemotherapy.
  • For all patients the 5-year actuarial survival rate was 40% with a median survival of 26 months.
  • CONCLUSIONS: Select patients with metastatic penile cancer that shows disease stabilization or a response to chemotherapy should be considered for surgical consolidation to extend survival.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / surgery. Penile Neoplasms / drug therapy. Penile Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Humans. Male. Middle Aged. Neoadjuvant Therapy

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17382727.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


8. Velazquez EF, Barreto JE, Rodriguez I, Piris A, Cubilla AL: Limitations in the interpretation of biopsies in patients with penile squamous cell carcinoma. Int J Surg Pathol; 2004 Apr;12(2):139-46
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limitations in the interpretation of biopsies in patients with penile squamous cell carcinoma.
  • Surgeons often perform small or superficial penile biopsies that are difficult to classify definitely with regard to a benign or malignant nature, and if malignant, cannot always be accurately subclassified.
  • Staging and therapeutic decisions rely on the identification, in these materials, of pathologic parameters related to prognosis.
  • In this study, we evaluated the accuracy and completeness of pathologic information obtained from biopsies of 57 consecutive patients with squamous cell carcinoma (SSC) of the penis, and compared it with the information obtained from penectomies.
  • The evaluated parameters were as follows: cancer diagnosis, histologic type, tumor grade, depth of invasion (anatomical levels), and vascular invasion.
  • In 2 patients with well-differentiated tumors a diagnosis of cancer could not be established in biopsy material.
  • In 17 cases (30%) there was a biopsy-penectomy discordance of histologic types, especially of verruciform and mixed carcinomas.
  • In summary, biopsies were useful for cancer diagnosis except in 2 differentiated variants of penile squamous cell carcinoma.
  • We conclude that clinical and pathologic staging of penile cancer, at least in our material, cannot depend on biopsy information alone.
  • Data from biopsies may be insufficient to make a decision whether to perform a groin dissection, or for prognostic evaluation in those patients in whom other treatment modalities (such as radiotherapy or chemotherapy) are being considered.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Penile Neoplasms / pathology. Penis / pathology

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15173919.001).
  • [ISSN] 1066-8969
  • [Journal-full-title] International journal of surgical pathology
  • [ISO-abbreviation] Int. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


9. Bevan-Thomas R, Slaton JW, Pettaway CA: Contemporary morbidity from lymphadenectomy for penile squamous cell carcinoma: the M.D. Anderson Cancer Center Experience. J Urol; 2002 Apr;167(4):1638-42
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Contemporary morbidity from lymphadenectomy for penile squamous cell carcinoma: the M.D. Anderson Cancer Center Experience.
  • PURPOSE: Inguinal lymphadenectomy can be curative in patients with small volume inguinal metastases and those with more significant adenopathy responding to combination chemotherapy.
  • We reviewed our recent experience with lymphadenectomy in patients with invasive penile cancer who were judged to require inguinal staging and therapeutic procedures to assess the incidence and magnitude of complications caused by this procedure, especially in those with no palpable adenopathy (prophylactic group).
  • The indications for dissection were prophylactic in 66 (62%) patients in whom a superficial dissection alone was completed on the ipsilateral side, therapeutic in 28 (26%) in whom superficial, deep and ipsilateral pelvic dissections were performed, and palliative in 12 (11%) undergoing extensive resection of inguinal and abdominal wall tissue after chemotherapy.
  • Minor postoperative complications included those requiring local wound débridement in the clinic, mild to moderate leg edema, seroma formation not requiring aspiration and minimal skin edge necrosis requiring no therapy.
  • Prophylactic and therapeutic dissections were associated with a lower incidence of complications compared with palliative dissections (p = 0.017 to 0.049).
  • Similarly the morbidity of therapeutic lymphadenectomy appeared acceptable, considering the potential therapeutic benefit.
  • Optimal candidates are those having a significant response to systemic chemotherapy whose groins are grossly uninfected.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Lymph Node Excision / adverse effects. Penile Neoplasms / surgery

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11912379.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Lutterbach J, Pagenstecher A, Weyerbrock A, Schultze-Seemann W, Waller CF: Early-stage penile carcinoma metastasizing to brain: case report and literature review. Urology; 2005 Aug;66(2):432
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Early-stage penile carcinoma metastasizing to brain: case report and literature review.
  • Early-stage penile squamous cell carcinoma with subsequent distant metastases is rare.
  • We report a case of a 35-year-old man with Stage pT1pN0 penile squamous cell carcinoma who underwent circumcision and bilateral inguinal lymphadenectomy.
  • Further in the disease course, the patient developed metastases in the kidney, adrenal gland, retroperitoneal lymph nodes, lung, and brain.
  • He underwent multiple resections, whole brain radiotherapy, and several chemotherapy regimens.
  • Forty months after the first diagnosis, the patient died of thromboembolic complications.
  • [MeSH-major] Brain Neoplasms / secondary. Carcinoma, Squamous Cell / secondary. Penile Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16098372.001).
  • [ISSN] 1527-9995
  • [Journal-full-title] Urology
  • [ISO-abbreviation] Urology
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


11. Sofikerim M, Gülmez I, Tokat F, Er O, Gülmez I: Epidermoid carcinoma of the lung with isolated penile metastasis. Can J Urol; 2007 Aug;14(4):3643-5
MedlinePlus Health Information. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Epidermoid carcinoma of the lung with isolated penile metastasis.
  • We report a case of epidermoid-cell carcinoma of the lung that developed a metastatic lesion in the penis.
  • He had a left pneumectomy and was diagnosed with epidermoid carcinoma of the lung at stage IIB (T2N1M0).
  • He was started on an adjuvant chemotherapy protocol consisting of cisplatin and paclitaxel.
  • He was admitted to our urology clinic with obstructive symptoms during urination and pain during penile erection.
  • Physical examination revealed a firm, 3 cm x 2 cm palpable mass on the radix of his penis.
  • A fine-needle aspiration biopsy of the penile mass revealed epidermoid carcinoma that was consistent with lung cancer.
  • The patient was considered to have penile metastasis from epidermoid carcinoma of the lung.
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Lung Neoplasms / pathology. Penile Neoplasms / secondary

  • Genetic Alliance. consumer health - Epidermoid Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17784986.001).
  • [ISSN] 1195-9479
  • [Journal-full-title] The Canadian journal of urology
  • [ISO-abbreviation] Can J Urol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Canada
  •  go-up   go-down


12. Otto T, Suhr J, Krege S, Rübben H: [Therapy of advanced penis carcinoma]. Urologe A; 2003 Nov;42(11):1466-9
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Therapy of advanced penis carcinoma].
  • [Transliterated title] Die Therapie des fortgeschrittenen Peniskarzinoms.
  • Skin infiltration and locoregional lymph node extension in metastatic penile cancer leads to destruction in the inguinal and perineal region.
  • The obligatorily superinfected defects require tension-free and extended coverage with immediate myocutaneous flaps after surgical resection.
  • Data concerning a prospective study for neoadjuvant chemotherapy with CMB followed by surgical tumor resection with immediate myocutaneous flap reconstruction are presented.
  • In 15 patients (median age: 69.7 years) suffering from squamous cell carcinoma of the penis (Tx, N3, M1 cutis), a surgical excision of the tumor was performed after neoadjuvant chemotherapy (median:2.4 cycles) and antibiotic pretreatment.
  • All patients received coverage of the femoral vessels with a musculus sartorius transfer on both sides.
  • An extended (up to 45x30 cm) tension-free coverage of groin defects was performed in two patients with a unilateral M. tensor fasciae latae flap (TFL) and in eight patients with a bilateral TFL.
  • One patient received a M. gluteus maximus flap (GMFL) on both sides, three patients were treated with a combination of M. rectus abdominis flap (RFL) and TFL, and one patient received a combination of two TFL, one GMFL as well as one RFL.
  • Of 31 myocutaneous pedicle flaps, 2 developed distant necrosis of the flap, in which one GMFL and one TFL were affected.
  • The covering of groin defects by the use of myocutaneous flaps, such as the M. tensor fasciae latae, M. rectus abdominis, and M. gluteus maximus flap, is a method of first choice in the primary treatment of even bacterially contaminated wounds or after radiation therapy.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Neoadjuvant Therapy. Penile Neoplasms / drug therapy
  • [MeSH-minor] Aged. Antibiotic Prophylaxis. Bleomycin / administration & dosage. Bleomycin / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Combined Modality Therapy. Graft Survival / drug effects. Humans. Lymph Node Excision. Lymphatic Metastasis. Male. Methotrexate / administration & dosage. Methotrexate / adverse effects. Microsurgery. Neoplasm Invasiveness. Neoplasm Staging. Skin / pathology. Superinfection / prevention & control. Surgical Flaps / blood supply. Surgical Wound Infection / prevention & control. Suture Techniques. Treatment Outcome. Wound Healing / drug effects

  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Plast Reconstr Surg. 2001 Dec;108(7):1998-2005 [11743391.001]
  • [Cites] Br J Plast Surg. 1987 Sep;40(5):485-7 [3676574.001]
  • [Cites] Urologe A. 1997 Mar;36(2):157-61 [9199044.001]
  • [Cites] J Urol. 1999 Jun;161(6):1823-5 [10332445.001]
  • [Cites] J Urol. 1982 Sep;128(3):599-601 [7120574.001]
  • [Cites] Urol Int. 1998;61(4):243-6 [10364759.001]
  • [Cites] Br J Plast Surg. 1982 Oct;35(4):413-9 [7139168.001]
  • [Cites] Urol Clin North Am. 1992 May;19(2):333-8 [1374199.001]
  • [Cites] J Urol. 2001 Oct;166(4):1384-5 [11547082.001]
  • [Cites] J Urol. 2003 Jan;169(1):118-20 [12478117.001]
  • [Cites] Nihon Hinyokika Gakkai Zasshi. 1983 Jul;74(7):1113-21 [6663941.001]
  • [Cites] Naunyn Schmiedebergs Arch Pharmacol. 1997 Dec;356(6):769-76 [9453463.001]
  • (PMID = 14624345.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] Comparative Study; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


13. de los Rios Osorio J, Castro Alvarez EA: [Analysis of 5000 vasectomies at a family planning clinic in Medellin-Colombia]. Arch Esp Urol; 2003 Jan-Feb;56(1):53-60
MedlinePlus Health Information. consumer health - Vasectomy.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Transliterated title] Análisis de 5000 vasectomías de un centro de planificación familiar en Medellín-Colombia.
  • OBJECTIVES: To study the evolution of 49 patients with squamous cell carcinoma of the penis.
  • METHODS: 49 patients who underwent surgery for squamous cell carcinoma of the penis (30 partial penile amputations, 11 total amputations and 7 circumcisions).
  • 27 inguinal lymphadenectomies, superficial, profound and ilio-obturator (2 cases), were performed due to persistent lymph nodes after penile amputation despite of antibiotic treatment for 4 weeks, or to high grade primary tumour.
  • 13 patients were found to have lymph node metastases after treatment, receiving posterior adjuvant treatment with radiotherapy, chemotherapy or a combination of them.
  • Patients were followed in relation to stage, cell differentiation degree, and presence or absence of positive lymph nodes and distant metastases.
  • 6 patients died from tumour dissemination, 2 of them were T2G2, one T2G1, and three T1G2; two additional patients died from causes different from the tumour, all of them being N+ at the time of diagnosis.
  • CONCLUSIONS: Penile squamous cell carcinoma is an aggressive tumour the evolution of which mainly depends on the local-regional stage at the time of diagnosis and cell differentiation; these factors will condition lymphadenectomy versus observation.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12701481.001).
  • [ISSN] 0004-0614
  • [Journal-full-title] Archivos españoles de urología
  • [ISO-abbreviation] Arch. Esp. Urol.
  • [Language] spa
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Spain
  •  go-up   go-down


14. Zhu Y, Li H, Yao XD, Zhang SL, Zhang HL, Shi GH, Yang LF, Yang ZY, Wang CF, Ye DW: Feasibility and activity of sorafenib and sunitinib in advanced penile cancer: a preliminary report. Urol Int; 2010;85(3):334-40
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Feasibility and activity of sorafenib and sunitinib in advanced penile cancer: a preliminary report.
  • INTRODUCTION: We describe our experience with sorafenib and sunitinib in the treatment of chemotherapy-refractory advanced penile squamous cell carcinoma (SCC).
  • PATIENTS AND METHODS: Between May 2008 and June 2009, 6 advanced penile cancer patients were treated with sorafenib or sunitinib in our center.
  • All of them had previously received at least two chemotherapy regimens.
  • Immunohistochemical staining of CD34 and Ki-67 was performed in 3 paired tumor tissues before and after treatment.
  • After molecular-targeted therapies, reduction in microvessel density and Ki-67 labeling index was observed in paired specimens.
  • Serum SCC antigen levels were decreased in 5 patients after 1 week of medication.
  • The patient who achieved partial response had an SCC antigen reduction of nearly 95% after treatment with sunitinib.
  • Serious adverse events were fatal infection and rupture of the femoral vessel, which were unlikely related to the medication.
  • CONCLUSIONS: The feasibility and activity of sorafenib and sunitinib in our series suggest that this approach may be a promising alternative in chemotherapy-refractory advanced penile SCC.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Benzenesulfonates / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Indoles / therapeutic use. Penile Neoplasms / drug therapy. Pyridines / therapeutic use. Pyrroles / therapeutic use
  • [MeSH-minor] Adult. Antigens, CD34 / biosynthesis. Humans. Immunohistochemistry / methods. Ki-67 Antigen / biosynthesis. Male. Middle Aged. Neoplasm Metastasis. Niacinamide / analogs & derivatives. Phenylurea Compounds. Positron-Emission Tomography / methods. Tomography, X-Ray Computed / methods. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • Hazardous Substances Data Bank. NICOTINAMIDE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 S. Karger AG, Basel.
  • (PMID = 20980789.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  • [Chemical-registry-number] 0 / Antigens, CD34; 0 / Antineoplastic Agents; 0 / Benzenesulfonates; 0 / Indoles; 0 / Ki-67 Antigen; 0 / Phenylurea Compounds; 0 / Pyridines; 0 / Pyrroles; 0 / sunitinib; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


15. Zhu Y, Ye DW, Yao XD, Zhang SL, Dai B, Zhang HL, Shen YJ: The value of squamous cell carcinoma antigen in the prognostic evaluation, treatment monitoring and followup of patients with penile cancer. J Urol; 2008 Nov;180(5):2019-23
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The value of squamous cell carcinoma antigen in the prognostic evaluation, treatment monitoring and followup of patients with penile cancer.
  • PURPOSE: We examined whether squamous cell carcinoma antigen has significant value for prognostic evaluation, treatment monitoring and followup in patients with penile cancer.
  • MATERIALS AND METHODS: Serum squamous cell carcinoma antigen was prospectively measured in 63 patients with penile squamous cell carcinoma from 2005 to 2007.
  • The normal range of squamous cell carcinoma antigen was set as less than 1.50 mug/l.
  • RESULTS: Of all patients 23.8% had a value of squamous cell carcinoma antigen that was greater than the upper limit of normal.
  • However, squamous cell carcinoma antigen could not accurately predict occult inguinal lymph node metastasis in clinically node negative cases.
  • Preoperatively squamous cell carcinoma antigen was an independent prognostic factor for disease-free survival in patients with node positive penile cancer (OR 0.13, p = 0.006).
  • Combining pretreatment squamous cell carcinoma antigen and the percent of decrease after surgery was informative for predicting disease recurrence.
  • The prognostic value of squamous cell carcinoma antigen was also observed in a small number of patients treated with chemotherapy.
  • During followup continuously increasing squamous cell carcinoma antigen indicated tumor progression without a significant lead time effect.
  • CONCLUSIONS: Squamous cell carcinoma antigen is not a sensitive marker of tumor burden.
  • However, it has prognostic significance for disease-free survival in patients with penile cancer treated with surgery.
  • [MeSH-major] Antigens, Neoplasm / metabolism. Biomarkers, Tumor / analysis. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / therapy. Penile Neoplasms / mortality. Penile Neoplasms / therapy. Serpins / metabolism
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Combined Modality Therapy. Evaluation Studies as Topic. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Multivariate Analysis. Neoplasm Staging. Probability. Prognosis. Proportional Hazards Models. Prospective Studies. Radiotherapy, Adjuvant. Risk Assessment. Sensitivity and Specificity. Statistics, Nonparametric. Survival Rate. Treatment Outcome. Urologic Surgical Procedures, Male / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18801542.001).
  • [ISSN] 1527-3792
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antigens, Neoplasm; 0 / Biomarkers, Tumor; 0 / Serpins; 0 / squamous cell carcinoma-related antigen
  •  go-up   go-down


16. Syed S, Eng TY, Thomas CR, Thompson IM, Weiss GR: Current issues in the management of advanced squamous cell carcinoma of the penis. Urol Oncol; 2003 Nov-Dec;21(6):431-8
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Current issues in the management of advanced squamous cell carcinoma of the penis.
  • Effective treatment of penile carcinoma incorporates three modalities: surgery, radiation and chemotherapy.
  • In certain patients radiation therapy may be utilized to eradicate the tumor and allow organ preservation.
  • For patients with locally advanced disease, multi-modality approaches incorporating adjuvant or neoadjuvant chemotherapy and radiation therapy need to be studied.
  • Finally, in the setting of metastatic disease, less toxic and more effective combination chemotherapy are sought.
  • Novel targeted therapies that have been successful in squamous cell carcinoma at other sites must also be studied in this disease.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Penile Neoplasms / therapy
  • [MeSH-minor] Chemotherapy, Adjuvant. Combined Modality Therapy. Humans. Male. Prognosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14693269.001).
  • [ISSN] 1078-1439
  • [Journal-full-title] Urologic oncology
  • [ISO-abbreviation] Urol. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 86
  •  go-up   go-down


17. Iborra F, Neuzillet Y, Méjean A, Lebret T: [Metastases from squamous cell carcinoma of the penis]. Prog Urol; 2008 Nov;18 Suppl 7:S392-5
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Metastases from squamous cell carcinoma of the penis].
  • [Transliterated title] Métastases des cancers du pénis.
  • Penile cancer is a rare carcinoma and visceral metastases are uncommon.
  • Metastasis diagnosis is carried out with TDM and MRI but markers can sometimes be helpful (ie SSCAg).
  • There is no referent chemotherapy, a trial has been started (CAVER).
  • [MeSH-major] Carcinoma, Squamous Cell / secondary. Penile Neoplasms / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19070821.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


18. Bissada NK, Yakout HH, Fahmy WE, Gayed MS, Touijer AK, Greene GF, Hanash KA: Multi-institutional long-term experience with conservative surgery for invasive penile carcinoma. J Urol; 2003 Feb;169(2):500-2
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Multi-institutional long-term experience with conservative surgery for invasive penile carcinoma.
  • PURPOSE: Invasive squamous cell carcinoma of the penis occurs on the glans, prepuce, glans and prepuce, coronal sulcus and shaft.
  • Penile squamous cell carcinoma subsequently invades local structures, corpora cavernosa and the urethra, and metastasizes to the inguinal lymph nodes.
  • Invasive squamous cell carcinoma of the penis usually requires total or partial penectomy.
  • We studied the effect of primary tumor resections tailored to the anatomical extent of the cancer with preservation of uninvolved structures in select patients with invasive penile squamous cell carcinoma.
  • MATERIALS AND METHODS: A total of 30 patients between 39 and 82 years old were treated with unconventional conservative surgical excision of the primary penile lesion.
  • Chemotherapy was given to 7 patients with extensive inguinal lymphadenopathy and to 2 of 5 with pathologically positive lymph nodes.
  • Tumor resection with no sacrifice of function was performed in 2 patients in whom 3 small recurrences developed.
  • Of the 7 patients with advanced lymphadenopathy 5 and of 5 patients with pathologically positive lymph nodes at presentation 1 died of the cancer but had no local recurrence in the penis.
  • CONCLUSIONS: In a minority of patients with anatomically suitable penile cancer conservative surgical techniques are safe and provide equal tumor control compared to conventional resections.
  • The anatomical situation and tumor characteristics should dictate the choice of treatment for the primary penile lesion.
  • Inguinal lymph nodes should be managed by appropriately established guidelines but should not influence the extent of primary penile lesion resection.
  • [MeSH-major] Penile Neoplasms / surgery. Urologic Surgical Procedures, Male / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Humans. Male. Middle Aged. Neoplasm Invasiveness. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12544296.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] United States
  •  go-up   go-down


19. Preis E, Jakse G: [The significance of inguinal lymphadenectomy in carcinoma of the penis]. Urologe A; 2006 Sep;45 Suppl 4:176-80

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The significance of inguinal lymphadenectomy in carcinoma of the penis].
  • The occurrence of inguinal lymph node metastases from squamous cell carcinoma of the penis depends on local tumor extension, tumor grade, and vascular invasion.
  • Whilst imaging techniques and fine needle biopsy can detect metastases to the inguinal nodes, resection of the superficial inguinal nodes remains the procedure of choice for diagnosis.
  • Chemotherapy and radiotherapy and the two combined have not been tested for efficacy, but are used individually before and after surgery, depending on the local tumor extent.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Lymph Node Excision / methods. Penile Neoplasms / surgery
  • [MeSH-minor] Germany. Humans. Inguinal Canal. Lymphatic Metastasis / pathology. Male. Neoplasm Invasiveness. Neoplasm Staging. Penis / pathology. Postoperative Complications / etiology. Practice Guidelines as Topic. Prognosis. Sentinel Lymph Node Biopsy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Semin Surg Oncol. 1990;6(4):241-2 [2389105.001]
  • [Cites] J Urol. 1987 May;137(5):880-2 [3573181.001]
  • [Cites] J Urol. 1986 Jul;136(1):38-41 [3712610.001]
  • [Cites] Eur Urol. 2005 May;47(5):601-6; discussion 606 [15826750.001]
  • [Cites] Urol Oncol. 2004 May-Jun;22(3):236-44; discussion 244-5 [15271324.001]
  • [Cites] J Urol. 1995 Dec;154(6):1999-2003 [7500444.001]
  • [Cites] J Urol. 1994 May;151(5):1239-43 [8158767.001]
  • [Cites] J Urol. 2003 Aug;170(2 Pt 1):359-65 [12853775.001]
  • [Cites] BJU Int. 2005 Mar;95(4):517-21 [15705071.001]
  • [Cites] J Urol. 2004 Aug;172(2):494-7 [15247712.001]
  • [Cites] Br J Urol. 1994 Nov;74(5):646-51 [7530129.001]
  • [Cites] J Urol. 1999 Jun;161(6):1823-5 [10332445.001]
  • [Cites] Int Urol Nephrol. 2002;34(2):245-50 [12775105.001]
  • [Cites] J Urol. 2003 Sep;170(3):783-6 [12913697.001]
  • [Cites] Urol Clin North Am. 1992 May;19(2):247-56 [1574815.001]
  • [Cites] Arch Ital Urol Androl. 1996 Jun;68(3):169-72 [8767505.001]
  • [Cites] BJU Int. 2001 Sep;88(5):473-83 [11589660.001]
  • [Cites] Acta Chir Scand. 1958 May 23;115(1-2):25-45 [13558905.001]
  • [Cites] J Urol. 1998 Nov;160(5):1770-4 [9783949.001]
  • [Cites] Eur Urol. 1994;26(2):123-8 [7957466.001]
  • [Cites] Cancer. 1955 Mar-Apr;8(2):371-8 [14352176.001]
  • [Cites] BJU Int. 2006 Jul;98(1):70-3 [16831146.001]
  • [Cites] J Urol. 2005 Sep;174(3):923-7; discussion 927 [16093989.001]
  • [Cites] Eur Urol. 1997;32(1):5-15 [9266225.001]
  • [Cites] BJU Int. 2000 Oct;86(6):690-3 [11069378.001]
  • [Cites] Br J Urol. 1993 Nov;72(5 Pt 2):817-9 [8281416.001]
  • [Cites] Cancer. 1977 Feb;39(2):456-66 [837331.001]
  • [Cites] Br J Urol. 1998 Mar;81(3):453-7 [9523669.001]
  • [Cites] J Urol. 2001 May;165(5):1633-4 [11342941.001]
  • [Cites] Br J Urol. 1965 Apr;37:211-22 [14282085.001]
  • [Cites] Urologe A. 2001 Jul;40(4):308-12 [11490865.001]
  • [Cites] BJU Int. 2006 Jun;97(6):1225-8 [16686716.001]
  • [Cites] J Urol. 2002 Apr;167(4):1638-42 [11912379.001]
  • [Cites] J Urol. 2003 Apr;169(4):1349-52 [12629358.001]
  • [Cites] Urol Clin North Am. 1992 May;19(2):267-76 [1574817.001]
  • [Cites] J Urol. 2001 Apr;165(4):1138-42 [11257655.001]
  • [Cites] Onkologie. 2005 Mar;28(3):135-8 [15772463.001]
  • [Cites] Mod Pathol. 2001 Oct;14(10):963-8 [11598165.001]
  • [Cites] Eur Urol. 2002 Sep;42(3):199-203 [12234502.001]
  • (PMID = 16933120.001).
  • [ISSN] 1433-0563
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 46
  •  go-up   go-down


20. Slampa P, Kost'áková G, Hynková L, Růzicková J, Horová H, Jezková B: [Conservative treatment for the penis carcinoma]. Cas Lek Cesk; 2004;143(9):589-93

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Conservative treatment for the penis carcinoma].
  • [Transliterated title] Konzervativní lécba karcinomu penisu.
  • No explicit recommendation has been determined in a treatment for the verified squamous cell penis carcinoma till now.
  • The application of ionizing radiation is included in traditional treatment methods for this disease, in addition to surgical operations and chemotherapy cure.
  • Radiotherapy has its place in the neoadjuvans treatment with the goal to reduce the disease extent.
  • This review is describing principles of the radiotherapy treatment for this disease.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Penile Neoplasms / radiotherapy
  • [MeSH-minor] Combined Modality Therapy. Humans. Male

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15532896.001).
  • [ISSN] 0008-7335
  • [Journal-full-title] Casopís lékar̆ů c̆eských
  • [ISO-abbreviation] Cas. Lek. Cesk.
  • [Language] cze
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Czech Republic
  • [Number-of-references] 19
  •  go-up   go-down


21. Skeel RT, Huang J, Manola J, Wilding G, Dreicer R, Walker P, Muggia F, Crawford ED, Dutcher JP, Loehrer PJ: A phase II study of 13-cis retinoic acid plus interferon alpha-2a in advanced stage penile carcinoma: an Eastern Cooperative Oncology Group study (E3893). Cancer Invest; 2003;21(1):41-6
Hazardous Substances Data Bank. 13-CIS-RETINOIC ACID .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A phase II study of 13-cis retinoic acid plus interferon alpha-2a in advanced stage penile carcinoma: an Eastern Cooperative Oncology Group study (E3893).
  • PURPOSE: Combined biological therapy with 13-cis-retinoic acid (13-cRA) and interferon alpha-2a (IFN alpha-2a) was reported to be highly effective in squamous cell carcinoma of the cervix and skin.
  • Squamous cell carcinoma of the penis is rare in the United States, accounting for less than 1/2% of all male malignancies.
  • Because of the association of infection with human papillomavirus with both carcinomas of the cervix and penis and their shared squamous cell histology, we carried out a phase II study of 13-cRA and IFN alpha-2a in carcinoma of the penis.
  • MATERIALS AND METHODS: Eighteen ambulatory patients with surgically unresectable, recurrent, and/or metastatic squamous cell carcinoma of the penis were treated with IFN alpha-2a, 3MU/day administered subcutaneously and 13-cRA, 1 mg/kg orally daily for at least eight weeks, unless intolerable toxicity occurred.
  • RESULTS: One patient was ineligible; one patient withdrew prior to treatment.
  • Fourteen patients had progressive disease as their only treatment effect.
  • No unexpected treatment-related toxicities were found on study.
  • CONCLUSION: In contrast to its benefit in squamous cell carcinomas of the cervix and skin, the combination of 13-cRA and IFN alpha-2a has low efficacy in advanced carcinoma of the penis.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Penile Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Anemia / chemically induced. Disease Progression. Fatigue / chemically induced. Fever / chemically induced. Humans. Hypertriglyceridemia / chemically induced. Interferon-alpha / administration & dosage. Interferon-alpha / adverse effects. Isotretinoin / administration & dosage. Isotretinoin / adverse effects. Life Tables. Male. Middle Aged. Recombinant Proteins. Survival Analysis. Treatment Failure

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12643008.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / CA14958; United States / NCI NIH HHS / CA / CA21115; United States / NCI NIH HHS / CA / CA23318; United States / NCI NIH HHS / CA / CA32102; United States / NCI NIH HHS / CA / CA42777; United States / NCI NIH HHS / CA / CA49883; United States / NCI NIH HHS / CA / CA58882; United States / NCI NIH HHS / CA / CA66636; United States / NCI NIH HHS / CA / CACA21076
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, U.S. Gov't, P.H.S.
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Interferon-alpha; 0 / Recombinant Proteins; 76543-88-9 / interferon alfa-2a; EH28UP18IF / Isotretinoin
  •  go-up   go-down


22. Phé V, Rouprêt M, Mottet N: [What's new in 2008 in the field of basic and clinical research in testicular and penile cancer?]. Prog Urol; 2009 May;19 Suppl 2:S51-5
MedlinePlus Health Information. consumer health - Testicular Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [What's new in 2008 in the field of basic and clinical research in testicular and penile cancer?].
  • [Transliterated title] Quelles nouveautes en 2008 dans le cancer du testicule et du pénis en recherche clinique et en recherche fondamentale ?
  • In stage I testis seminomas, data comparing 1 course of chemotherapy by carboplatin (AUC: 7) to retroperitoneal radiotherapy in adjuvant treatment were updated.
  • Localizations of recurrences were different, depending on adjuvant treatment.
  • In stage I non seminomatous testis cancer, active surveillance could be possible if there were not any vascular embols.
  • Chemotherapy by 1 course of BEP was superior to retroperitoneal lymph node dissection in stage I.
  • In Leydig cell tumors, conservative surgery was possible.
  • In penile cancer management, dynamic sentinel node biopsy could be interesting.
  • Carbon-dioxide laser microsurgery only for initially invasive squamous cell carcinoma of the penis could be proposed.
  • [MeSH-major] Penile Neoplasms / therapy. Testicular Neoplasms / therapy

  • Genetic Alliance. consumer health - Testicular cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19447329.001).
  • [ISSN] 1166-7087
  • [Journal-full-title] Progrès en urologie : journal de l'Association française d'urologie et de la Société française d'urologie
  • [ISO-abbreviation] Prog. Urol.
  • [Language] fre
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 17
  •  go-up   go-down


23. Borchers H, Jakse G: [Lymphadenectomy for penile cancer. Diagnostic and prognostic significance as well as therapeutic benefit]. Urologe A; 2005 Jun;44(6):657-61

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Lymphadenectomy for penile cancer. Diagnostic and prognostic significance as well as therapeutic benefit].
  • Lymphadenectomy is an essential part of diagnosis and treatment of the squamous cell carcinoma of the penis.
  • Lymphadenectomy is performed depending on various characteristics of penile cancer such as depth of invasion, tumor grade, invasion into the corpora cavernosa, invasion into vascular and lymphatic vessels.
  • The limits of lymphadenectomy are extended to the radical type of dissection when the frozen section indicates cancer.
  • Neoadjuvant chemotherapy is reasonable for patients with bulky nodes fixed to the skin or fascia because this improves respectability, freedom from local recurrence and increases survival.
  • Adjuvant chemo- and/or radio-therapy are reserved for extended disease or palliative situations.
  • [MeSH-major] Lymph Node Excision / methods. Lymph Nodes / pathology. Lymph Nodes / surgery. Penile Neoplasms / pathology. Penile Neoplasms / surgery. Prostatectomy / methods. Risk Assessment / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Curr Opin Urol. 2003 Nov;13(6):467-72 [14560140.001]
  • [Cites] J Urol. 1996 Nov;156(5):1637-42 [8863559.001]
  • [Cites] J Urol. 2003 Aug;170(2 Pt 1):359-65 [12853775.001]
  • [Cites] BJU Int. 2005 Mar;95(4):517-21 [15705071.001]
  • [Cites] Int Urol Nephrol. 2002;34(2):245-50 [12775105.001]
  • [Cites] J Urol. 2002 Jul;168(1):76-80 [12050496.001]
  • [Cites] Arch Ital Urol Androl. 1996 Jun;68(3):169-72 [8767505.001]
  • [Cites] BJU Int. 2001 Sep;88(5):473-83 [11589660.001]
  • [Cites] Ann Oncol. 1997 Nov;8(11):1089-98 [9426328.001]
  • [Cites] J Urol. 2002 Jan;167(1):89-92; discussion 92-3 [11743282.001]
  • [Cites] Acta Oncol. 1988;27(6b):823-4 [2466471.001]
  • [Cites] J Urol. 1992 Mar;147(3):630-2 [1538445.001]
  • [Cites] J Urol. 2002 Oct;168(4 Pt 1):1638-9 [12356050.001]
  • [Cites] Urol Int. 1999;62(4):229-33 [10567890.001]
  • [Cites] Urologe A. 2003 Nov;42(11):1466-9 [14624345.001]
  • [Cites] J Urol. 2000 Jan;163(1):100-4 [10604324.001]
  • [Cites] BJU Int. 2000 Oct;86(6):690-3 [11069378.001]
  • [Cites] Cancer. 1977 Feb;39(2):456-66 [837331.001]
  • [Cites] J Urol. 2001 May;165(5):1506-9 [11342906.001]
  • [Cites] BJU Int. 2003 Aug;92(3):248-50 [12887477.001]
  • [Cites] Urologe A. 2001 Jul;40(4):308-12 [11490865.001]
  • [Cites] J Urol. 1994 May;151(5):1244-9 [7512656.001]
  • [Cites] J Urol. 2003 Apr;169(4):1349-52 [12629358.001]
  • [Cites] J Urol. 2001 Apr;165(4):1138-42 [11257655.001]
  • [Cites] Urology. 2001 Jul;58(1):65-8 [11445481.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1997 Jul 1;38(4):713-22 [9240637.001]
  • [Cites] Mod Pathol. 2001 Oct;14(10):963-8 [11598165.001]
  • [Cites] Int Urol Nephrol. 1999;31(4):525-31 [10668948.001]
  • (PMID = 15891865.001).
  • [ISSN] 0340-2592
  • [Journal-full-title] Der Urologe. Ausg. A
  • [ISO-abbreviation] Urologe A
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Number-of-references] 21
  •  go-up   go-down


24. Langeland T, Engh V: Topical use of tacrolimus and squamous cell carcinoma on the penis. Br J Dermatol; 2005 Jan;152(1):183-5
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Topical use of tacrolimus and squamous cell carcinoma on the penis.
  • [MeSH-major] Carcinoma, Squamous Cell / chemically induced. Immunosuppressive Agents / adverse effects. Penile Neoplasms / chemically induced. Tacrolimus / adverse effects
  • [MeSH-minor] Balanitis / drug therapy. Humans. Male. Middle Aged

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentOn] Br J Dermatol. 2003 Nov;149(5):960-7 [14632799.001]
  • (PMID = 15656830.001).
  • [ISSN] 0007-0963
  • [Journal-full-title] The British journal of dermatology
  • [ISO-abbreviation] Br. J. Dermatol.
  • [Language] eng
  • [Publication-type] Case Reports; Comment; Letter
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Immunosuppressive Agents; WM0HAQ4WNM / Tacrolimus
  •  go-up   go-down






Advertisement